• Hejin Jia, Zhenguang Wang, Yao Wang, Yang Liu, Hanren Dai, Chuan Tong, Yelei Guo, Bo Guo, Dongdong Ti, Xiao Han, Qingming Yang, Zhiqiang Wu, and Weidong Han.
• Molecular & Immunological Department, Bio-therapeutic Department, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing, 100853, China.
• J Hematol Oncol. 2019 Jun 10; 12 (1): 57.

BackgroundChimeric antigen receptor T (CAR-T) cell therapy simultaneously against CD19 and CD22 is an attractive strategy to address the antigen escape relapse after CD19-directed CAR-T cell therapies. However, the potential of optimizing the durability of remission by this approach in patients with B cell acute lymphoblastic leukemia (B-ALL) remains a critical unanswered question so far.Case PresentationWe treated an adult patient with relapsed and refractory B-ALL after haploidentical hematopoietic stem cell transplantation (HSCT) by administering haploidentical CAR-T cells targeting both CD19 and CD22 following preparative lymphodepleting chemotherapy. This patient has remained in minimal residual disease-negative remission for more than 14 months and has been tapered off graft versus host disease prophylaxis.ConclusionsCAR simultaneously targeting CD19 and CD22 has the potential of inducing long-term remission in patients with B-ALL.

24 keywords...

hide…